---
schema_version: "secwatch.filing_event.v1"
accession: "0001516551-24-000108"
form_type: "8-K"
ticker: "SKYE"
cik: "0001516551"
company_name: "Skye Bioscience, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:30:45.680557+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025

## Summary
- Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
- Cash and equivalents $76.5M including restricted $9.1M; court order allows release of $9M restriction before year-end.
- Phase 2 obesity trial for nimacimab enrolling; interim data Q2 2025, topline data Q4 2025.
- Preclinical DIO mouse model: nimacimab achieved up to 16% weight loss vs vehicle, with fat loss and lean mass preservation.
- Appointed Dr. Puneet Arora as Chief Medical Officer and Paul Grayson as Chairman.

## SEC filing metadata
- accession: 0001516551-24-000108
- form_type: 8-K
- ticker: SKYE
- cik: 0001516551
- company_name: Skye Bioscience, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000108/0001516551-24-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1516551/000151655124000108/skye-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001516551-24-000108
- JSON: https://secwatch.observer/filing/0001516551-24-000108.json
- Plain text: https://secwatch.observer/filing/0001516551-24-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.